Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has required an alternative method of administration that d...

Descripción completa

Detalles Bibliográficos
Autores principales: Yildiz Pekoz, Ayca, Akbal Dagistan, Ozlem, Fael, Hanan, Culha, Meltem, Erturk, Aybige, Basarir, Nur Sena, Sahin, Gokben, Serhatli, Muge, Cakirca, Gamze, Tekin, Saban, Sen, Leyla Semiha, Sevim, Mustafa, Mulazimoglu Durmusoglu, Lutfiye, Yegen, Berrak C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448368/
https://www.ncbi.nlm.nih.gov/pubmed/36062490
http://dx.doi.org/10.1080/10717544.2022.2118398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448368/
https://www.ncbi.nlm.nih.gov/pubmed/36062490
http://dx.doi.org/10.1080/10717544.2022.2118398

Ejemplares similares